Answers are grounded in this paper and cite their sources.
This cross-sectional study assesses formulary coverage, patient cost-sharing, and prior authorization requirements for lower-emission inhalers among patients with asthma or chronic obstructive pulmonary disease across US commercial insurance plans.
No takes yet. Share an insight, caveat, or question.
Parthasarathi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: